Pioglitazone + Glimepiride Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: Pioglitazone 15 mg/30 mg + Glimepiride 1 mg/2 mg/ 4 mg
Reference Brands: Duetact
Category:
Diabetes
This combination works synergistically to control blood glucose in type 2 diabetes. Pioglitazone, a thiazolidinedione, improves insulin sensitivity in muscle and fat, while Glimepiride, a sulfonylurea, stimulates insulin release from pancreatic β-cells. Together, they enhance glycemic control, reduce insulin resistance, and lower HbA1c levels effectively.
Pioglitazone + Glimepiride Tablets is available in Tablets
and strengths such as Pioglitazone 15 mg/30 mg + Glimepiride 1 mg/2 mg/ 4 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pioglitazone + Glimepiride Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pioglitazone + Glimepiride Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pioglitazone and Glimepiride combination tablets are used in managing type 2 diabetes mellitus by enhancing insulin sensitivity and stimulating pancreatic insulin secretion. In the USA, fixed-dose combinations are less commonly marketed, with Actoplus Met (Pioglitazone + Metformin) being more prevalent. However, some Pioglitazone–Glimepiride formulations are approved in select EU countries and widely available as generics in Asia. In the EU, products must meet EMA standards for bioequivalence and fixed-dose rationale. These combinations are prescribed when monotherapy fails to control blood glucose. Pharmatradz.com connects buyers with certified suppliers offering GMP-compliant combination antidiabetic medications globally, including Pioglitazone-Glimepiride tablets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing